TP53 and B-cell chronic lymphocytic leukemia: Interestingly, reflecting pre-clinical data showing a TP53-independent induced apoptosis of CLL cells [11], venetoclax then showed a potent activity in high-risk CLL harboring a 17p deletion in a phase II study [12], leading to US Food and Drug Agency (FDA) approval in this setting in 2016.